AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes
AstraZeneca and HUTCHMED submitted a U.S. New Drug Application for savolitinib plus Tagrisso in EGFR-mutated lung cancer with MET changes. The combination is not yet approved in the U.S. The application is based on the SAFFRON trial, which showed statistically significant improvements in progression-free and overall survival compared to chemotherapy. The FDA has not announced whether it will review the application or set a decision date.
How this was made
The 30-second read
Why it matters
The FDA filing signals AstraZeneca's intent to expand Tagrisso's indication, potentially increasing its market share and revenue if approved.
Market read
Regulatory progress on a novel oncology combo could move AstraZeneca's stock and influence the broader biotech sector.
What to watch
The combination is not yet approved in the U.S.; reliance on Chinese partner Hutchmed and lack of disclosed efficacy numbers limit immediate upside.
Background
AstraZeneca's Tagrisso is a standard EGFR‑mutated lung‑cancer therapy; resistance via MET is a known challenge. Savolitinib is a MET inhibitor approved in China.
Ticker impact
AstraZeneca filed a U.S. NDA for the savolitinib plus Tagrisso combination targeting MET‑driven resistance in EGFR‑mutated lung cancer.
potential upside if the FDA accepts the application and later grants approval; short‑term pressure may be modest until a decision is announced
Regulatory filings for novel oncology combos are material events; the market will price in the probability of approval, creating upside bias.
Market effects
Could boost the oncology/targeted‑therapy segment and increase investor focus on MET‑inhibitor strategies.
May affect European biotech sentiment and Chinese partner Hutchmed's valuation indirectly.
Adds a new candidate to the global lung‑cancer treatment pipeline, relevant for investors tracking FDA oncology approvals.
Counterpoint
If the FDA delays or rejects the filing, the stock could face disappointment despite the hype.
Key entities
- CompanyAstraZeneca
Global pharmaceutical firm seeking FDA approval for a new lung‑cancer combo.
- CompanyHutchmed
Chinese developer of savolitinib, partner in the filing.
